Pacific Biosciences (PACB) delivered earnings and revenue surprises of +15.39% and +7.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences (PACB) delivered earnings and revenue surprises of +15.39% and +7.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) delivered earnings and revenue surprises of +491.67% and +24.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.
PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.